Pausing your titration: the dose-hold most prescribers don't mention

What standard titration looks like

Every approved GLP-1 starts low and escalates over several months to a maintenance dose. For semaglutide (Wegovy):

• Weeks 1 to 4: 0.25 mg weekly
• Weeks 5 to 8: 0.5 mg weekly
• Weeks 9 to 12: 1.0 mg weekly
• Weeks 13 to 16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

For tirzepatide (Zepbound, Mounjaro), the climb is similar with different specific doses, escalating to a maximum of 15 mg weekly.

The labels describe this as the recommended schedule. They do not describe it as the required schedule. The label language is explicit: if a patient does not tolerate a higher dose, the prescriber may delay escalation. (Wegovy label, Section 2.2.)

Why women pause

There are three good reasons, all common, all underused.

Reason one: weight loss is too fast

If you are losing more than 1% of body weight per week for several weeks running, the rate of loss is in the territory that produces:

• Loose skin (slower re-tensioning than the loss)
• Worse muscle loss (more aggressive caloric deficit)
• "Ozempic face" (see our article on the topic)
• Fatigue and electrolyte shifts

Staying on your current dose for an additional 4 to 8 weeks lets the body catch up. The drug is still working. Your loss continues, just at a more sustainable pace.

Reason two: side effects are not yet manageable

If nausea, fatigue, or constipation are still active at the current dose, climbing to the next one is likely to make things worse. The four-week titration assumes you have adjusted; if you have not, the climb is premature.

Most prescribers, asked directly, will agree that staying at the current dose until you are comfortable is reasonable. Few prescribers will volunteer this option without being asked.

Reason three: you are losing weight without needing to climb

Some women hit a satisfying rate of loss at 1.0 mg weekly of semaglutide and never need 2.4 mg. The label maximum is a maximum, not a target. If your current dose is producing the results you want and is well-tolerated, why move?

This is particularly relevant for women whose goal is a modest amount of weight loss, say, 10 to 15% of body weight, rather than the larger reductions some women aim for.

What pausing actually looks like

The mechanics are simple. You skip the dose-up. You continue on your current weekly dose. You stay there for as long as it makes sense.

In practice:

• The next dose increase is delayed by 4 to 12 weeks
• Your weekly injection continues at the same dose
• The next prescription refill picks up the same dose
• Your prescriber adjusts the plan in your record

There is no special procedure. There is a conversation.

How to bring it up with your prescriber

A direct, non-confrontational way to frame the conversation:

"I've been doing well on my current dose. I'd like to stay here for another month or two before we move up. Is there any medical reason we need to keep climbing on schedule?"

The answer will almost always be "no." If your prescriber pushes back, the question to ask is what specifically would change if you moved up, and whether that specific thing is worth the side-effect or cosmetic cost.

Some prescribers are habit-driven and follow the titration schedule without thinking. A small number are dosing-protocol strict for legitimate clinical reasons. Most are happy to pause if asked. Many will be relieved to have a patient who has actually thought about the trade-off.

When pausing is the wrong answer

Pausing is not always right. Times when continuing the titration is the better move:

• You are early in the journey and have not yet seen meaningful weight loss. Pausing at 0.5 mg of semaglutide if you have not lost weight is unlikely to help. The titration is designed to find the dose that works.
• You have type-2 diabetes and the drug's glucose effects are still suboptimal. Diabetes management may require pushing to a higher dose regardless of weight effects.
• Side effects are mild and clearly improving. If nausea has gone from severe to occasional and you can see the trend, climbing through the dose increase may continue that adaptation.

What pausing buys you

A small list of what a pause can produce, in order of likelihood:

• A more sustainable rate of loss: closer to 0.5 to 0.75% per week instead of 1.5%+
• Better tolerability: adapting to a dose for longer often means adapting to a dose for good
• Time to build the muscle and habit foundation: the longer you stay at a dose, the more time the rest of your plan has to keep up
• Reduced cosmetic effects: slower loss is gentler on skin
• A clear conversation with your prescriber about what your treatment goals actually are

What this is not

This is not a recommendation to avoid the maximum dose. For many women, the maximum is the right dose and the trial data is built around it. The point is not to be conservative for the sake of it. The point is to be deliberate.

For what happens when people step down to a lower dose after losing weight, read staying on a lower GLP-1 dose.

What to do with this

A pause changes the dose and therefore the ceiling. Put your current dose in and the calculator recalculates how much you are likely to manage, which is the number that actually moves when you hold.

Recalculate at your dose

Sources

1. FDA Prescribing Information, Wegovy. Section 2.2, Recommended Dosage. Label
2. FDA Prescribing Information, Zepbound. Section 2. Label
3. Wilding JPH et al. STEP 1 long-term outcomes. NEJM 2021. NEJM
4. Garvey WT et al. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract 2016. PubMed

Medical disclaimer: Dosing decisions belong with your prescriber. This article is educational. See our full medical disclaimer.